Trial Profile

A Phase 2 Study of REOLYSIN in Combination With Gemcitabine for Patients With Advanced Pancreatic Adenocarcinoma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Jul 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pelareorep (Primary) ; Gemcitabine
Indications Pancreatic cancer
Focus Therapeutic Use
Sponsors Oncolytics Biotech

Most Recent Events

06 Jul 2015 According to Oncolytics Biotech media release, final data has been presented at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer.
06 Jul 2015 Results published in Oncolytics Biotech Media Release.
29 May 2015 Results of the correlation of outcomes with skeletal muscle changes were presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com